Efficacy of Recombinant Luteinizing Hormone for Controlled Ovarian Hyperstimulation in Assisted Reproduction Cycles
|
|
Kim, Yong-Jin
(Department of Obstetrics and Gynecology, College of Medicine, Seoul National University)
Ku, Seung-Yup (Department of Obstetrics and Gynecology, College of Medicine, Seoul National University) Jee, Byung-Chul (Institute of Reproductive Medicine and Population, Medical Research Center, Seoul National University) Suh, Chang-Suk (Department of Obstetrics and Gynecology, College of Medicine, Seoul National University) Kim, Seok-Hyun (Department of Obstetrics and Gynecology, College of Medicine, Seoul National University) Choi, Yong-Min (Department of Obstetrics and Gynecology, College of Medicine, Seoul National University) Kim, Jung-Gu (Department of Obstetrics and Gynecology, College of Medicine, Seoul National University) Moon, Shin-Yong (Department of Obstetrics and Gynecology, College of Medicine, Seoul National University) |
| 1 | Balasch J, Creus M, Fabregues F, Civico S, Carmona F, Puerto B, et al. The effect of exogenous luteinizing hormone (LH) on oocyte viability: evidence from a comparative study using recombinant human follicle-stimulating hormone (FSH) alone or in combination with recombinant LH for ovarian stimulation in pituitary-suppressed women undergoing assisted reproduction. J Assist Reprod Genet 2001; 18: 250-6 DOI ScienceOn |
| 2 | Lisi F, Rinaldi L, Fishel S, Caserta D, Lisi R, Campbell A. Evaluation of two doses of recombinant luteinizing hormone supplementation in an unselected group of women undergoing follicular stimulation for in vitro fertilization. Fertil Steril 2005; 83: 309-15 DOI ScienceOn |
| 3 | Sills ES, Levy DP, Moomjy M, McGee M, Rosenwaks Z. A prospective, randomized comparison of ovulation induction using highly purified follicle-stimulating hormone alone and with recombinant human luteinizing hormone in in-vitro fertilization. Hum Reprod 1999; 14: 2230-5 DOI |
| 4 | Levi-Setti PE, Cavagna M, Bulletti C. Recombinant gonadotrophins associated with GnRH antagonist (cetrorelix) in ovarian stimulation for ICSI: comparison of r-FSH alone and in combination with r-LH. Eur J Obstet Gynecol Reprod Biol 2006; 126: 212-6 DOI ScienceOn |
| 5 | Reame N, Sauder SE, Kelch RP, Marshall JC. Pulsatile gonadotropin secretion during the human menstrual cycle: evidence for altered frequency of gonadotropin-releasing hormone secretion. J Clin Endocrinol Metab 1984; 59: 328-37 DOI |
| 6 | Ku SY, Suh CS, Kim SH, Choi YM, Kim JG, Moon SY. A pilot study of the use of low dose human menopausal gonadotropin in ovulation induction. Eur J Obstet Gynecol Reprod Biol 2003; 109: 55-9 DOI ScienceOn |
| 7 | Filicori M, Cognigni GE, Taraborrelli S, Parmegiani L, Bernardi S, Ciampaglia W. Intracytoplasmic sperm injection pregnancy after low-dose human chorionic gonadotropin alone to support ovarian folliculogenesis. Fertil Steril 2002; 78: 414-6 DOI ScienceOn |
| 8 | Fair T. Follicular oocyte growth and acquisition of developmental competence. Anim Reprod Sci 2003; 78: 203-16 DOI ScienceOn |
| 9 | Kolibianakis EM, Zikopoulos K, Schiettecatte J, Smitz J, Tournaye H, Camus M, et al. Profound LH suppression after GnRH antagonist administration is associated with a significantly higher ongoing pregnancy rate in IVF. Hum Reprod 2004; 19: 2490-6 DOI ScienceOn |
| 10 | De Placido G, Alviggi C, Mollo A, Strina I, Ranieri A, Alviggi E, et al. Effects of recombinant LH (rLH) supplementation during controlled ovarian hyperstimulation (COH) in normogonadotrophic women with an initial inadequate response to recombinant FSH (rFSH) after pituitary downregulation. Clin Endocrinol (Oxf) 2004; 60: 637-43 DOI ScienceOn |
| 11 | Alviggi C, Mollo A, Clarizia R, De Placido G. Exploiting LH in ovarian stimulation. Reprod Biomed Online 2006; 12: 221-33 DOI PUBMED ScienceOn |
| 12 | Chung K, Krey L, Katz J, Noyes N. Evaluating the role of exogenous luteinizing hormone in poor responders undergoing in vitro fertilization with gonadotropin-releasing hormone antagonists. Fertil Steril 2005; 84: 313-8 DOI ScienceOn |
| 13 | Fabregues F, Creus M, Penarrubia J, Manau D, Vanrell JA, Balasch J. Effects of recombinant human luteinizing hormone supplementation on ovarian stimulation and the implantation rate in down-regulated women of advanced reproductive age. Fertil Steril 2006; 85: 925-31 DOI ScienceOn |
| 14 | Acevedo B, Sanchez M, Gomez JL, Cuadros J, Ricciarelli E, Hernandez ER. Luteinizing hormone supplementation increases pregnancy rates in gonadotropin-releasing hormone antagonist donor cycles. Fertil Steril 2004; 82: 343-7 DOI ScienceOn |
| 15 | Shoham Z. The clinical therapeutic window for luteinizing hormone in controlled ovarian stimulation. Fertil Steril 2002; 77: 1170-7 DOI ScienceOn |
| 16 | Tarlatzis B, Tavmergen E, Szamatowicz M, Barash A, Amit A, Levitas E, et al. The use of recombinant human LH (lutropin alfa) in the late stimulation phase of assisted reproduction cycles: a double-blind, randomized, prospective study. Hum Reprod 2006; 21: 90-4 DOI ScienceOn |
| 17 | Orvieto R, Meltcer S, Rabinson J, Gemer O, Anteby EY, Nahum R. Does day 3 luteinizing-hormone level predict IVF success in patients undergoing controlled ovarian stimulation with GnRH analogues? Fertil Steril 2008 |
| 18 | Garcia-Velasco JA, Coelingh Bennink HJ, Epifanio R, Escudero E, Pellicer A, Simon C. High-dose recombinant LH add-back strategy using high-dose GnRH antagonist is an innovative protocol compared with standard GnRH antagonist. Reprod Biomed Online 2007; 15: 280-7 DOI PUBMED ScienceOn |
| 19 | Huirne JA, van Loenen AC, Schats R, McDonnell J, Hompes PG, Schoemaker J, et al. Dose-finding study of daily GnRH antagonist for the prevention of premature LH surges in IVF/ICSI patients: optimal changes in LH and progesterone for clinical pregnancy. Hum Reprod 2005; 20: 359-67 DOI ScienceOn |
| 20 | Grondahl ML, Borup R, Lee YB, Myrhoj V, Meinertz H, Sorensen S. Differences in gene expression of granulosa cells from women undergoing controlled ovarian hyperstimulation with either recombinant follicle-stimulating hormone or highly purified human menopausal gonadotropin. Fertil Steril 2008 |
| 21 | Lisi F, Rinaldi L, Fishel S, Lisi R, Pepe G, Picconeri MG, et al. Use of recombinant FSH and recombinant LH in multiple follicular stimulation for IVF: a preliminary study. Reprod Biomed Online 2001; 3: 190-4 DOI PUBMED ScienceOn |
| 22 | Yanaihara A, Yorimitsu T, Motoyama H, Ohara M, Kawamura T. The decrease of serum luteinizing hormone level by a gonadotropin-releasing hormone antagonist following the mild IVF stimulation protocol for IVF and its clinical outcome. J Assist Reprod Genet 2008; 25: 115-8 DOI |
| 23 | Griesinger G, Schultze-Mosgau A, Dafopoulos K, Schroeder A, Schroer A, von Otte S, et al. Recombinant luteinizing hormone supplementation to recombinant follicle-stimulating hormone induced ovarian hyperstimulation in the GnRH-antagonist multiple-dose protocol. Hum Reprod 2005; 20: 1200-6 DOI ScienceOn |
| 24 | Marrs R, Meldrum D, Muasher S, Schoolcraft W, Werlin L, Kelly E. Randomized trial to compare the effect of recombinant human FSH (follitropin alfa) with or without recombinant human LH in women undergoing assisted reproduction treatment. Reprod Biomed Online 2004; 8: 175-82 DOI PUBMED ScienceOn |
| 25 | Gutman G, Barak V, Maslovitz S, Amit A, Lessing JB, Geva E. Recombinant luteinizing hormone induces increased production of ovarian follicular adiponectin in vivo: implications for enhanced insulin sensitivity. Fertil Steril 2008 PUBMED |
| 26 | Ferraretti AP, Gianaroli L, Magli MC, D'Angelo A, Farfalli V, Montanaro N. Exogenous luteinizing hormone in controlled ovarian hyperstimulation for assisted reproduction techniques. Fertil Steril 2004; 82: 1521-6 DOI ScienceOn |
| 27 | De Placido G, Mollo A, Clarizia R, Strina I, Conforti S, Alviggi C. Gonadotropin-releasing hormone (GnRH) antagonist plus recombinant luteinizing hormone vs. a standard GnRH agonist short protocol in patients at risk for poor ovarian response. Fertil Steril 2006; 85: 247-50 DOI ScienceOn |
| 28 | Filicori M, Cognigni GE, Samara A, Melappioni S, Perri T, Cantelli B, et al. The use of LH activity to drive folliculogenesis: exploring uncharted territories in ovulation induction. Hum Reprod Update 2002; 8: 543-57 DOI ScienceOn |
| 29 | De Placido G, Alviggi C, Perino A, Strina I, Lisi F, Fasolino A, et al. Recombinant human LH supplementation versus recombinant human FSH (rFSH) step-up protocol during controlled ovarian stimulation in normogonadotrophic women with initial inadequate ovarian response to rFSH. A multicentre, prospective, randomized controlled trial. Hum Reprod 2005; 20: 390-6De Placido G, Alviggi C, Perino A, Strina I, Lisi F, Fasolino A, et al. Recombinant human LH supplementation versus recombinant human FSH (rFSH) step-up protocol during controlled ovarian stimulation in normogonadotrophic women with initial inadequate ovarian response to rFSH. A multicentre, prospective, randomized controlled trial. Hum Reprod 2005; 20: 390-6 DOI |
| 30 | Baruffi RL, Mauri AL, Petersen CG, Felipe V, Martins AM, Cornicelli J, et al. Recombinant LH supplementation to recombinant FSH during induced ovarian stimulation in the GnRH-antagonist protocol: a meta-analysis. Reprod Biomed Online 2007; 14: 14-25 DOI ScienceOn |
| 31 | Gutman G, Barak V, Maslovitz S, Amit A, Lessing JB, Geva E. Regulation of vascular endothelial growth factor-A and its soluble receptor sFlt-1 by luteinizing hormone in vivo: implication for ovarian follicle angiogenesis. Fertil Steril 2008; 89: 922-6 DOI ScienceOn |
| 32 | Kolibianakis EM, Kalogeropoulou L, Griesinger G, Papanikolaou EG, Papadimas J, Bontis J, et al. Among patients treated with FSH and GnRH analogues for in vitro fertilization, is the addition of recombinant LH associated with the probability of live birth? A systematic review and meta-analysis. Hum Reprod Update 2007; 13: 445-52 DOI ScienceOn |
| 33 | De Placido G, Mollo A, Alviggi C, Strina I, Varricchio MT, Ranieri A, et al. Rescue of IVF cycles by HMG in pituitary down-regulated normogonadotrophic young women characterized by a poor initial response to recombinant FSH. Hum Reprod 2001; 16: 1875-9 DOI ScienceOn |
| 34 | Cedrin-Durnerin I, Grange-Dujardin D, Laffy A, Parneix I, Massin N, Galey J, et al. Recombinant human LH supplementation during GnRH antagonist administration in IVF/ICSI cycles: a prospective randomized study. Hum Reprod 2004; 19: 1979-84 DOI ScienceOn |
| 35 | Barrenetxea G, Agirregoikoa JA, Jimenez MR, de Larruzea AL, Ganzabal T, Carbonero K. Ovarian response and pregnancy outcome in poor-responder women: a randomized controlled trial on the effect of luteinizing hormone supplementation on in vitro fertilization cycles. Fertil Steril 2008; 89: 546-53 DOI ScienceOn |
| 36 | Al-Inany H, Aboulghar MA, Mansour RT, Proctor M. Recombinant versus urinary gonadotrophins for triggering ovulation in assisted conception. Hum Reprod 2005; 20: 2061-73 DOI ScienceOn |
| 37 | Durnerin CI, Erb K, Fleming R, Hillier H, Hillier SG, Howles CM, et al. Effects of recombinant LH treatment on folliculogenesis and responsiveness to FSH stimulation. Hum Reprod 2008; 23: 421-6 DOI ScienceOn |
| 38 | Hillier SG, Whitelaw PF, Smyth CD. Follicular oestrogen synthesis: the 'two-cell, two-gonadotrophin' model revisited. Mol Cell Endocrinol 1994; 100: 51-4 DOI ScienceOn |
| 39 | Chappel SC, Howles C. Reevaluation of the roles of luteinizing hormone and follicle-stimulating hormone in the ovulatory process. Hum Reprod 1991; 6: 1206-12 DOI PUBMED |
| 40 | The ganirelix dose-finding study group. A double-blind, randomized, dose-finding study to assess the efficacy of the gonadotrophin-releasing hormone antagonist ganirelix (Org 37462) to prevent premature luteinizing hormone surges in women undergoing ovarian stimulation with recombinant follicle stimulating hormone (Puregon). Hum Reprod 1998; 13: 3023-31 DOI |
| 41 | Themmen APN, Huhtaniemi IT. Mutations of gonadotropins and gonadotropin receptors: elucidating the physiology and pathophysiology of pituitary-gonadal function. Endocr Rev 2000; 21: 551-83 DOI ScienceOn |
| 42 | Hurwitz JM, Santoro N. Inhibins, activins, and follistatin in the aging female and male. Semin Reprod Med 2004; 22: 209-17 DOI ScienceOn |
| 43 | Mochtar MH, Van der V, Ziech M, van Wely M. Recombinant Luteinizing Hormone (rLH) for controlled ovarian hyperstimulation in assisted reproductive cycles. Cochrane Database Syst Rev 2007: CD005070 |
| 44 | Sauer MV, Thornton MH, 2nd, Schoolcraft W, Frishman GN. Comparative efficacy and safety of cetrorelix with or without mid-cycle recombinant LH and leuprolide acetate for inhibition of premature LH surges in assisted reproduction. Reprod Biomed Online 2004; 9: 487-93 DOI PUBMED ScienceOn |
| 45 | Ruvolo G, Bosco L, Pane A, Morici G, Cittadini E, Roccheri MC. Lower apoptosis rate in human cumulus cells after administration of recombinant luteinizing hormone to women undergoing ovarian stimulation for in vitro fertilization procedures. Fertil Steril 2007; 87: 542-6 DOI ScienceOn |
| 46 | Kolibianakis EM, Collins J, Tarlatzis B, Papanikolaou E, Devroey P. Are endogenous LH levels during ovarian stimulation for IVF using GnRH analogues associated with the probability of ongoing pregnancy? A systematic review. Hum Reprod Update 2006; 12: 3-12 DOI ScienceOn |
| 47 | Liu KE, Greenblatt EM. Elevated day 3 follicle-stimulating hormone/luteinizing hormone ratio >or= 2 is associated with higher rates of cancellation in in vitro fertilization-embryo transfer cycles. Fertil Steril 2008; 90: 297-301 DOI ScienceOn |
| 48 | Humaidan P, Bungum M, Bungum L, Yding Andersen C. Effects of recombinant LH supplementation in women undergoing assisted reproduction with GnRH agonist down-regulation and stimulation with recombinant FSH: an opening study. Reprod Biomed Online 2004; 8: 635-43 DOI PUBMED ScienceOn |
| 49 | Westergaard LG, Laursen SB, Andersen CY. Increased risk of early pregnancy loss by profound suppression of luteinizing hormone during ovarian stimulation in normogonadotrophic women undergoing assisted reproduction. Hum Reprod 2000; 15: 1003-8 DOI ScienceOn |
| 50 | O'Dea L, O'Brien F, Currie K, Hemsey G. Follicular development induced by recombinant luteinizing hormone (LH) and follicle-stimulating hormone (FSH) in anovulatory women with LH and FSH deficiency: evidence of a threshold effect. Curr Med Res Opin 2008 |
| 51 | Shoham Z, Schacter M, Loumaye E, Weissman A, MacNamee M, Insler V. The luteinizing hormone surge--the final stage in ovulation induction: modern aspects of ovulation triggering. Fertil Steril 1995; 64: 237-51 DOI PUBMED |
| 52 | Gadkari RA, Sandhya S, Sowdhamini R, Dighe RR. The antigen binding sites of various hCG monoclonal antibodies show homology to different domains of LH receptor. Mol Cell Endocrinol 2007; 260-262: 23-32 DOI ScienceOn |
| 53 | Filicori M, Cognigni GE, Pocognoli P, Ciampaglia W, Bernardi S. Current concepts and novel applications of LH activity in ovarian stimulation. Trends Endocrinol Metab 2003; 14: 267-73 DOI ScienceOn |
 |
Korea Institute of Science and Technology Information
Gwahangno, Yuseong-gu, Daejeon, 305-806, Korea TEL : +82-42-869-1752
Copyright (c) 2009 KISTI. All Rights Reserved. For more information mail to
webmaster
